69 results about "Glypican" patented technology

The invention relates to a dual-targeting genetically modified immunologic effector cell aiming at GPC3 (glypican-3) and ASGPR1 (asialoglycoprotein receptor 1) and applications of the dual-targeting genetically modified immunologic effector cell. The invention discloses the gene-modified immunologic effector cell capable of simultaneously identifying GPC3 and ASGPR1 for the first time, and the gene-modified immunologic effector cell can be used for the treatment of the GPC3 and ASGPR1 double-positive tumor, such as liver cancer.

Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.

The invention provides primers and probes for specifically detecting human HCC (Hepatocellular Carcinoma) marker, including a primer and a probe (Seq ID No.1-3) for detecting glypican cDNA (complementary deoxyribonucleic acid) and a primer and a probe (Seq ID No.4-6) used for detecting alpha fetoprotein cDNA. The invention also provides a detection kit containing the primers and the probes and used for detecting the marker of human HCC by multiplex real-time fluorescence quantification PCR (Polymerase Chain Reaction). According to the invention, by virtue of the multiplex real-time fluorescence quantification PCR, alpha fetoprotein messenger RNA (AFP mRNA) and glypican messenger RNA (GPC3 mRNA) in human HCC at the mRNA level can be detected; the detection method is simple, quick, high in sensitivity and strong in specificity; the whole detection reaction only lasts for 100min. An important technical support is provided for the specific detection of canceration of human HCC.

The invention discloses a GPC3 (glypican-3) monoclonal antibody hybridoma strain 8G6, and a preparation method and application thereof, which belong to the technical field of cell engineering. The preservation code of the GPC3 monoclonal antibody hybridoma strain 8G6 is CGMCC (china general microbiological culture collection center) No.5427. The preparation method of the GPC3 monoclonal antibody hybridoma strain 8G6 includes: using GPC3 protein as immunogen to immunize a mouse; and fusing mouse splenocytes having serum titer more than 1:104 with SP2 / 0 myeloma cells, using an HATRPMI-1640 medium to screen fusion cells, and finally obtaining the hybridoma strain 8G6 by ELISA (enzyme-linked immunosorbent assay) and repeated limiting dilution. The GPC3 monoclonal antibody hybridoma strain 8G6 is high in yield of secretory antibodies, and is easy to survive, and the secreted monoclonal antibodies are high in titer, sensitive in reaction, easy to detect, low in production cost and widely applicable to detection of GPC3 protein expression.

The invention discloses a method for detecting the inhibiting ability of silent GPC-3 (glypican-3) gene transcription on a hepatocellular carcinoma transplanted tumor in a nude mouse. The method includes: 1) designing and synthesizing 4 pairs of miRNA oligomeric single-strand DNA specific to a target gene consensus sequence, then synthesizing the corresponding dsDNA, inserting the dsDNA into a vector to construct 4 recombinant plasmids, and picking out the recombinant plasmid with the highest interference efficiency through fluorescence quantitative PCR; 2) transfecting the recombinant plasmid with the highest interference efficiency into HepG2 cells to construct transfected HepG2 cells, and performing screening, thus obtaining a stably transfected HepG2 cell; 3) inoculating the stably transfected HepG2 cell to the nude mouse subcutaneously to construct a human hepatocellular carcinoma tumor-bearing nude mouse model; and 4) then determining the growth state of the stably transfected HepG2 cell in the human hepatocellular carcinoma tumor-bearing nude mouse model. The method provided by the invention can be employed to detect the inhibiting ability of silent GPC-3 gene transcription on a hepatocellular carcinoma transplanted tumor in the nude mouse, and can be used for research of GPC-3 on transplanted tumors.

Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer—both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts—whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.

The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards.

The present invention relates to a nanobody of Glypican 3 with outstanding high stability and a preparation method thereof, and also relates to the amino acid sequence of the nanobody, a gene coding sequence and an expression vector capable of expressing the nanobody and host cell. The amino acid sequence of the nanobody to GPC3 provided by the present invention is shown in SEQ ID NO: 7, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO: 8. The GPC3 nanobody involved in the present invention can specifically recognize liver cancer cells with high GPC3 expression by binding to the GPC3 expressed on the cell membrane. The antibody has outstanding high stability, and can be used in the functional research of GPC3, and can also be used in the development of diagnostic reagents and therapeutic drugs for hepatocellular carcinoma.